Comparison 3. HFOV versus CV subgrouped by use of surfactant.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death by 36 to 37 weeks or discharge	16	3233	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.80, 1.10]
1.1 Routine surfactant	15	3168	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.80, 1.10]
1.2 No routine surfactant	1	65	Risk Ratio (M‐H, Fixed, 95% CI)	1.01 [0.40, 2.58]
2 CLD at 36 to 37 weeks PMA or discharge in survivors	16	2699	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.78, 0.96]
2.1 Routine surfactant	15	2648	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.80, 0.97]
2.2 No routine surfactant	1	51	Risk Ratio (M‐H, Fixed, 95% CI)	0.23 [0.07, 0.73]
3 Death or CLD at 36 to 37 weeks PMA or discharge	16	3233	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.83, 0.97]
3.1 Routine surfactant	15	3168	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.84, 0.98]
3.2 No routine surfactant	1	65	Risk Ratio (M‐H, Fixed, 95% CI)	0.52 [0.29, 0.94]
4 Gross pulmonary air leak	10	2089	Risk Ratio (M‐H, Fixed, 95% CI)	1.15 [0.90, 1.49]
4.1 Routine surfactant	9	2024	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.87, 1.49]
4.2 No routine surfactant	1	65	Risk Ratio (M‐H, Fixed, 95% CI)	1.32 [0.65, 2.71]
5 Intraventricular haemorrhage ‐ grades 3 or 4	16	3300	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.84, 1.19]
5.1 Routine surfactant	15	3235	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.84, 1.19]
5.2 No routine surfactant	1	65	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.33, 2.34]
6 Periventricular leukomalacia	15	3214	Risk Ratio (M‐H, Fixed, 95% CI)	0.87 [0.65, 1.16]
6.1 Routine surfactant	15	3214	Risk Ratio (M‐H, Fixed, 95% CI)	0.87 [0.65, 1.16]
6.2 No routine surfactant	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]